Amgen’s Kyprolis launches in the UK for relapsed multiple myeloma
Amgen’s Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone is now available in the UK for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Kyprolis is the first licensed irreversible proteasome inhibitor for use in combination treatment of patients with relapsed multiple myeloma.
Click on this link for more information.
